[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647558":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":41,"centralContacts":45,"locations":54,"responsibleParty":65,"collaborators":49,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":49,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":49,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":95,"whyStopped":49,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Ondokuz Mayıs University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group QLB","EXPERIMENTAL","LQLB (Active) + Sham ITM",[13,14],"Procedure: Lateral Quadratus Lumborum Block","Drug: ıv morphine PCA",{"label":16,"type":10,"description":17,"interventionNames":18},"Group ITM","ITM (Active) + Sham QLB",[14,19],"Procedure: Intrathecal morphine",[21,28,35],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Lateral Quadratus Lumborum Block","Active Lateral QLB Local anesthetic: 0.25% bupivacaine, 0.4 mL\u002Fkg perside (maximum 30 mL per side). Maximum total dose: Bupivacaine ≤2.5 mg\u002Fkg (maximum approximately 150 mg). Timing: Immediately after completion of surgery. The patient will be positioned supine or in a slight lateral decubitus position. A high-frequency linear US transducer (5-12 MHz) will be placed on the anterolateral abdominal wall at the T12-L1 level. The fascial plane will be identified under ultrasound guidance. A 22-gauge, 100-mm needle will be advanced using an in-plane approach, and after negative aspiration, the local anesthetic will be injected incrementally with hydrodissection confirming correct spread.\n\nSham ITM: The spinal anesthesia technique will be identical to that of the active ITM group. Morphine will be replaced with 0.2 mL preservative-free normal saline, while maintaining an identical syringe volume (2.7 mL) and appearance.",[9],[27],"Lateral QLB",{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","ıv morphine PCA","A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg\u002Fkg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg\u002F kg (IBW). No basal infusion will be used.",[16,9],[34],"PCA",{"type":22,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Intrathecal morphine","Hyperbaric 0.5% bupivacaine 12.5 mg, fentanyl 20 µg, and morphine 80 µg (0.08 mg). Spinal anesthesia will be performed at the L3-L4 or L4-L5 intervertebral space using a 25-gauge Quincke spinal needle. The study solution will be prepared to a total volume of 2.7 mL.\n\nSham QLB Following completion of surgery, the patient will be positioned in the lateral decubitus position. The ultrasound transducer will be placed over the lateral QLB scanning window. A 22-gauge needle will be advanced into the skin and subcutaneous tissue only, without entering the fascial plane. To maintain procedural standardization and preserve blinding, 1-2 mL of normal saline will be injected into the subcutaneous tissue. Procedure duration, patient positioning, ultrasound probe placement, and dressing application will be identical to those used for the active lateral QLB-I procedure. A sterile dressing will be applied at the end of the procedure.",[16],[40],"ITM",[42],{"name":43,"affiliation":5,"role":44},"Burhan Dost","PRINCIPAL_INVESTIGATOR",[46,51],{"name":43,"role":47,"phone":48,"phoneExt":49,"email":50},"CONTACT","+903623121919",null,"burhandost@hotmail.com",{"name":52,"role":47,"phone":48,"phoneExt":49,"email":53},"Esra Turunc","esra.kiymaz.ek@gmail.com",[55],{"facility":56,"status":49,"city":57,"state":49,"zip":49,"country":58,"countryCode":49,"cosmosGeoPoint":59,"geoPoint":64,"contacts":49},"Ondokuz Mayis University","Samsun","Turkey (Türkiye)",{"type":60,"coordinates":61},"Point",[62,63],36.3361,41.27976,{"lat":63,"lon":62},{"type":44,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":49,"oldOrganization":49},"BURHAN DOST","Director","100647558","lateral-ql-block-vs-intrathecal-morphine-for-cesarean-section-100647558",false,"NCT07712783","Lateral QL Block vs Intrathecal Morphine for Cesarean Section","Comparison of the Analgesic Efficacy of Lateral Quadratus Lumborum Block and Intrathecal Morphine for Postoperative Pain Management Following Cesarean Delivery Under Spinal Anesthesia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged between 18 and 45 years.\n* Singleton term pregnancy (≥37 weeks of gestation).\n* American Society of Anesthesiologists (ASA) physical status II.\n* Scheduled to undergo elective cesarean delivery via a Pfannenstiel incision.\n* Planned to receive spinal anesthesia for cesarean delivery.\n* Provision of written informed consent following a comprehensive explanation of the study.\n* Sufficient cognitive capacity to understand and complete the study assessment instruments, including the Numeric Rating Scale (NRS) and the ObsQoR-11T.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any of the study medications, including morphine, bupivacaine, or fentanyl.\n* Coagulopathy (international normalized ratio \\[INR\\] \\>1.5 or platelet count \\\u003C100,000\u002Fmm³).\n* Current treatment with anticoagulant or antiplatelet agents (e.g., heparin, low-molecular-weight heparin, or aspirin \\>100 mg\u002Fday).\n* Infection, hematoma, or skin lesion at the planned block insertion site.\n* Diagnosis of preeclampsia, eclampsia, or HELLP syndrome.\n* Placenta previa, placenta accreta spectrum, or placental abruption.\n* Gestational diabetes mellitus or chronic hypertension.\n* Emergency cesarean delivery indicated because of fetal distress.\n* Conversion to general anesthesia during cesarean delivery.\n* History of chronic pain syndrome (e.g., fibromyalgia, lumbar disc herniation, or neuropathic pain).\n* Regular use of opioids or psychotropic medications within the preceding 3 months.\n* Diagnosis of epilepsy, severe anxiety disorder, or major depressive disorder.\n* Obesity (body mass index \\>35 kg\u002Fm²).\n* Severe systemic disease, including New York Heart Association (NYHA) class III or IV heart failure, hepatic or renal failure, advanced respiratory disease, or obstructive sleep apnea.\n* Advanced pulmonary disease requiring continuous positive airway pressure (CPAP) therapy.\n* Inadequate spinal anesthesia or the requirement for supplemental intraoperative analgesia.\n* Surgical duration exceeding 120 minutes.\n* Excessive intraoperative blood loss (≥1,000 mL) or the need for blood transfusion.","FEMALE","18 Years","45 Years",{"count":79,"type":80},56,"ESTIMATED","INTERVENTIONAL",[83],"NA","Effective postoperative analgesia after cesarean delivery is essential for maternal recovery, early mobilization, breastfeeding, and maternal-infant bonding. Although intrathecal morphine (ITM) is considered the gold standard for post-cesarean analgesia, its use is associated with opioid-related adverse effects. Ultrasound-guided lateral quadratus lumborum block (QLB-I) has emerged as a promising alternative. This randomized, double-blind, non-inferiority trial aims to compare the postoperative analgesic efficacy of lateral QLB-I with ITM. Secondary outcomes include postoperative opioid consumption, pain scores, opioid-related adverse effects, quality of recovery (ObsQoR-11T), and maternal satisfaction.",[86,87,88],"Anesthesia","Postoperative Pain","Regional Anesthesia",[90,91,92,93,94],"cesarean delivery","postoperative opioid consumption","postoperative pain","lateral quadratus lumborum block","intrathecal morphine","NOT_YET_RECRUITING","2026-07-14",{"date":98,"type":99},"2026-07-17","ACTUAL",{"date":101,"type":80},"2026-07-15",{"date":103,"type":80},"2026-12-01",{"name":5,"class":6},1]